FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912503557> ?p ?o ?g. }

• W2912503557 abstract "A tenosynovial giant cell tumor (TGCT) is a locally aggressive benign neoplasm arising from intra- or extra-articular tissue. Diffuse TGCT (D-TGCT) most commonly develops in the knee, followed by the hip, ankle, elbow, and shoulder. Surgical removal is the only effective treatment option for the patients. However, a local recurrence rate as high as 47% has been reported. Recently, we revealed that zaltoprofen, a nonsteroidal anti-inflammatory drug possessing the ability to activate peroxisome proliferator-activated receptor gamma (PPARγ), can inhibit the proliferation of TGCT stromal cells via PPARγ. PPARγ is a ligand-activated transcription factor that belongs to the nuclear hormone receptor superfamily. It plays an important role in the differentiation of adipocytes from precursor cells and exhibits antitumorigenic effects on certain malignancies. Therefore, we are conducting this investigator-initiated clinical trial to evaluate whether zaltoprofen is safe and effective for patients with D-TGCT or unresectable localized TGCT (L-TGCT). This study is a randomized, placebo-controlled, double-blind, multicenter trial to evaluate the safety and efficacy of zaltoprofen for patients with D-TGCT or L-TGCT. For the treatment group, zaltoprofen 480 mg/day will be administered for 48 weeks; the placebo group will receive similar dosages without zaltoprofen. Twenty participants in each group are needed in this trial (40 participants total). The primary outcome is the progression-free rate at 48 weeks after treatment administration. “Progression” is defined as any serious events (1. Repetitive joint swelling due to hemorrhage, 2. Joint range of motion limitation, 3. Invasion of adjacent cartilage or bone, 4. Severe joint space narrowing, 5. Increase in tumor size) requiring surgical interventions. We hypothesize that the zaltoprofen group will have a higher progression-free rate compared to that of the placebo group at 48 weeks. This is the first study to evaluate the efficacy of zaltoprofen in patients with D-TGCT or unresectable L-TGCT. We believe that the results of this trial will validate a novel treatment option, zaltoprofen, to stabilize disease progression for TGCT patients. University Hospital Medical Information Network (UMIN) Clinical Trials Registry ( UMIN000025901 ) registered on 4/01/2017." @default.
• W2912503557 created "2019-02-21" @default.
• W2912503557 creator A5009180170 @default.
• W2912503557 creator A5010692199 @default.
• W2912503557 creator A5020130249 @default.
• W2912503557 creator A5027207215 @default.
• W2912503557 creator A5028483263 @default.
• W2912503557 creator A5032191719 @default.
• W2912503557 creator A5035537632 @default.
• W2912503557 creator A5036808755 @default.
• W2912503557 creator A5044214575 @default.
• W2912503557 creator A5048210816 @default.
• W2912503557 creator A5056400625 @default.
• W2912503557 creator A5056965210 @default.
• W2912503557 creator A5061154739 @default.
• W2912503557 creator A5063047785 @default.
• W2912503557 creator A5065764983 @default.
• W2912503557 creator A5079732218 @default.
• W2912503557 creator A5081080411 @default.
• W2912503557 creator A5088078553 @default.
• W2912503557 date "2019-02-09" @default.
• W2912503557 modified "2023-10-14" @default.
• W2912503557 title "Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol" @default.
• W2912503557 cites W1967057044 @default.
• W2912503557 cites W1968980738 @default.
• W2912503557 cites W1988828169 @default.
• W2912503557 cites W1995210963 @default.
• W2912503557 cites W2005296135 @default.
• W2912503557 cites W2005674716 @default.
• W2912503557 cites W2005998329 @default.
• W2912503557 cites W2019607817 @default.
• W2912503557 cites W2030127438 @default.
• W2912503557 cites W2034034179 @default.
• W2912503557 cites W2047591801 @default.
• W2912503557 cites W2050352100 @default.
• W2912503557 cites W2056734036 @default.
• W2912503557 cites W2068711694 @default.
• W2912503557 cites W2088404163 @default.
• W2912503557 cites W2120633854 @default.
• W2912503557 cites W2136299409 @default.
• W2912503557 cites W2136950996 @default.
• W2912503557 cites W2137172911 @default.
• W2912503557 cites W2148476235 @default.
• W2912503557 cites W2154669801 @default.
• W2912503557 cites W2162352227 @default.
• W2912503557 cites W2173681478 @default.
• W2912503557 cites W2227907422 @default.
• W2912503557 cites W2268757118 @default.
• W2912503557 cites W2270511696 @default.
• W2912503557 cites W4318444803 @default.
• W2912503557 doi "https://doi.org/10.1186/s12891-019-2453-z" @default.
• W2912503557 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6368706" @default.
• W2912503557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30738433" @default.
• W2912503557 hasPublicationYear "2019" @default.
• W2912503557 type Work @default.
• W2912503557 sameAs 2912503557 @default.
• W2912503557 citedByCount "8" @default.
• W2912503557 countsByYear W29125035572020 @default.
• W2912503557 countsByYear W29125035572021 @default.
• W2912503557 countsByYear W29125035572022 @default.
• W2912503557 countsByYear W29125035572023 @default.
• W2912503557 crossrefType "journal-article" @default.
• W2912503557 hasAuthorship W2912503557A5009180170 @default.
• W2912503557 hasAuthorship W2912503557A5010692199 @default.
• W2912503557 hasAuthorship W2912503557A5020130249 @default.
• W2912503557 hasAuthorship W2912503557A5027207215 @default.
• W2912503557 hasAuthorship W2912503557A5028483263 @default.
• W2912503557 hasAuthorship W2912503557A5032191719 @default.
• W2912503557 hasAuthorship W2912503557A5035537632 @default.
• W2912503557 hasAuthorship W2912503557A5036808755 @default.
• W2912503557 hasAuthorship W2912503557A5044214575 @default.
• W2912503557 hasAuthorship W2912503557A5048210816 @default.
• W2912503557 hasAuthorship W2912503557A5056400625 @default.
• W2912503557 hasAuthorship W2912503557A5056965210 @default.
• W2912503557 hasAuthorship W2912503557A5061154739 @default.
• W2912503557 hasAuthorship W2912503557A5063047785 @default.
• W2912503557 hasAuthorship W2912503557A5065764983 @default.
• W2912503557 hasAuthorship W2912503557A5079732218 @default.
• W2912503557 hasAuthorship W2912503557A5081080411 @default.
• W2912503557 hasAuthorship W2912503557A5088078553 @default.
• W2912503557 hasBestOaLocation W29125035571 @default.
• W2912503557 hasConcept C126322002 @default.
• W2912503557 hasConcept C142724271 @default.
• W2912503557 hasConcept C168563851 @default.
• W2912503557 hasConcept C198451711 @default.
• W2912503557 hasConcept C204787440 @default.
• W2912503557 hasConcept C27081682 @default.
• W2912503557 hasConcept C71924100 @default.
• W2912503557 hasConceptScore W2912503557C126322002 @default.
• W2912503557 hasConceptScore W2912503557C142724271 @default.
• W2912503557 hasConceptScore W2912503557C168563851 @default.
• W2912503557 hasConceptScore W2912503557C198451711 @default.
• W2912503557 hasConceptScore W2912503557C204787440 @default.
• W2912503557 hasConceptScore W2912503557C27081682 @default.
• W2912503557 hasConceptScore W2912503557C71924100 @default.
• W2912503557 hasIssue "1" @default.
• W2912503557 hasLocation W29125035571 @default.
• W2912503557 hasLocation W29125035572 @default.
• W2912503557 hasLocation W29125035573 @default.
• W2912503557 hasLocation W29125035574 @default.

• next